Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease.

[1]  C. Aguilar-Salinas,et al.  Metabolic modes of action of the statins in the hyperlipoproteinemias. , 1998, Atherosclerosis.

[2]  P. Vicini,et al.  The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[3]  P. Macfarlane,et al.  Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). , 1998, Circulation.

[4]  A. Cooper.  Hepatic uptake of chylomicron remnants. , 1997, Journal of lipid research.

[5]  F. Pileggi,et al.  Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease. , 1996, Atherosclerosis.

[6]  J. O’Keefe,et al.  Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. , 1995, The American journal of cardiology.

[7]  J. Mamo,et al.  CLEARANCE OF CHYLOMICRON‐LIKE LIPID EMULSIONS IS INCREASED IN NORMAL RABBITS BUT NOT IN HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDAEMIC RABBITS FOLLOWING TREATMENT WITH CHOLESTYRAMINE OR PRAVASTATIN , 1994, Clinical and experimental pharmacology & physiology.

[8]  A. Hamsten,et al.  Postprandial lipoproteins and progression of coronary atherosclerosis. , 1994, Atherosclerosis.

[9]  E. Moriguchi,et al.  Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. , 1993, Clinical biochemistry.

[10]  T. D. de Bruin,et al.  Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. , 1993, Metabolism: clinical and experimental.

[11]  B. Levkau,et al.  The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants. , 1991, The Biochemical journal.

[12]  A. Hofman,et al.  Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[13]  G. Coetzee,et al.  Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. , 1990, The Journal of clinical investigation.

[14]  K. Einarsson,et al.  Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. , 1990, The New England journal of medicine.

[15]  K. Cianflone,et al.  Modulation of chylomicron remnant metabolism by an hepatic hydroxymethylglutaryl coenzyme A reductase inhibitor. , 1990, Metabolism: Clinical and Experimental.

[16]  P. Edwards,et al.  Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. , 1985, The Journal of biological chemistry.

[17]  R. Maranhão,et al.  Metabolism of protein-free lipid emulsion models of chylomicrons in rats. , 1985, Biochimica et biophysica acta.

[18]  A. Gotto,et al.  Postprandial lipemia. A key for the conversion of high density lipoprotein2 into high density lipoprotein3 by hepatic lipase. , 1984, The Journal of clinical investigation.

[19]  D. Porte,et al.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man. , 1973, The Journal of clinical investigation.

[20]  H. Oliveira,et al.  Simultaneous measurements of chylomicron lipolysis and remnant removal using a doubly labeled artificial lipid emulsion: studies in normolipidemic and hyperlipidemic subjects. , 1994, Journal of lipid research.